EUCTR2019-002626-67-ES进行中（未招募）1 期
EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS - Safety and efficacy of bortezomib, lenalidomide and dexamethasone in multiple myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Informed consent form.
- •Untreated multiple myeloma.
- •IMWG criteria to start treatment
- •No major contraindication to treatment trial drugs.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 240
排除标准
- •Active concurrent disease precluding treatment.
- •Prior treatment for multiple myeloma.
- •Hypersensibility to bortezomib, lenalidomide or treatment excipients.
研究者
相似试验
已完成
不适用
To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.Multiple myelomaJPRN-UMIN000007838Kanshinetsu Multiple Myeloma Group47
已完成
不适用
To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantatioMultiple myelomaJPRN-UMIN000007880Kanshinetsu Multiple Myeloma Group35
招募中
不适用
Pharmacokinetics and clinical outcomes of bortezomib in patients with newly diagnosed myelomamultiple myelomaJPRN-UMIN000006257Division of Hematology, Department of Medicine, Keio University, School of Meidicine40
已完成
不适用
Safety and Efficacy of Bortezomib inaddtion to Adriamycin and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies ; A PhaseI/II, Multicentre, Open-Label, Single-Arm StudyRelapse/Refractory Multiple MyelomaJPRN-UMIN000001210Division of Medical Oncology, Hematology and Infectious Disease, Department of Medicine, Fukuoka University28
招募中
2 期
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Networkimmunocytomalymphoplasmacytic lymphomaWaldenstroms Macroglobulinemia10018865NL-OMON30654Academisch Medisch Centrum5